HIV/AIDS

Proposed change to Medicaid line extension definition ignores importance of critical improvements in treatments

  • by

In comments recently submitted to the administration, PhRMA raised concerns with a number of changes included in the Centers for Medicare & Medicaid Services (CMS) Medicaid proposed rule. Today, we’re diving deeper into CMS’s proposal to vastly expand the types of medicines that would fall… Read More »Proposed change to Medicaid line extension definition ignores importance of critical improvements in treatments

Commercial health plans have increased patients’ out-of-pocket costs by over 50% in some therapeutic areas

  • by

According to a recent IQVIA analysis, commercial health plans have increased patients’ average out-of-pocket costs for brand medicines by over 50% in some therapeutic areas since 2015. Notably, of the seven therapeutic areas that IQVIA analyzed, including anticoagulants, asthma/COPD, depression, diabetes, HIV, multiple sclerosis and… Read More »Commercial health plans have increased patients’ out-of-pocket costs by over 50% in some therapeutic areas

Ending the HIV Epidemic (EHE) Funding Tracker

  • by

This tracker provides up-to-date data on federal Ending the HIV Epidemic (EHE( funding, including an overview of funding mechanisms by year, agency, grant mechanism, and jurisdiction. It will be updated over time.

The Global HIV/AIDS Epidemic

  • by

This updated fact sheet provides the latest data on the global HIV/AIDS epidemic, including impact by region, treatment and prevention efforts, and an overview of the U.S. and global responses to the epidemic.

Insurance Coverage and Viral Suppression Among People with HIV in the United States, 2015-2018

Health insurance coverage and access to care improve health outcomes, including viral suppression, for people with HIV in the United States. Prior research has demonstrated that implementation of the Affordable Care Act (ACA) in 2014 increased coverage among people with HIV and that certain forms… Read More »Insurance Coverage and Viral Suppression Among People with HIV in the United States, 2015-2018

Quantifying PEPFAR’s Role for Women and Girls: Analysis of Monitoring, Evaluation, and Reporting Indicator Data, 2016-2019

Women and girls represent more than half of all people living with HIV worldwide, and HIV is the leading cause of death among women aged 15-49. This analysis sought to quantify PEPFAR’s role for women and girls in key program areas, analyzing data over time… Read More »Quantifying PEPFAR’s Role for Women and Girls: Analysis of Monitoring, Evaluation, and Reporting Indicator Data, 2016-2019